STA
VIVO

Summit Trail Advisors’s Meridian Bioscience Inc VIVO Stock Holding History

Summit Trail Advisors’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-275
Closed -$4K – 1811
2017
Q4 		$4K Buy
+275
New +$4.03K ﹤0.01% 1504

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Summit Trail Advisors's VIVO Position: Q1 2018 in Review

Summit Trail Advisors sold out of Meridian Bioscience Inc (VIVO) in Q1 2018, closing a stake of 275 shares — an estimated $4K sold.

Summit Trail Advisors first reported a position in VIVO in Q4 2017 and held it in 1 quarter. The position peaked at $4K in Q4 2017. 186 funds tracked by Wall St. Rank hold VIVO as of Q1 2018.

  • Summit Trail Advisors reported no remaining Meridian Bioscience Inc position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 275 Meridian Bioscience Inc shares in Q1 2018, an estimated $4K.
  • Summit Trail Advisors first reported a position in Meridian Bioscience Inc in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's Meridian Bioscience Inc position peaked at $4K in Q4 2017.
  • 186 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.